Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States.
Mol Aspects Med. 2013 Feb;34(1):71-83. doi: 10.1016/j.mam.2012.10.005. Epub 2012 Oct 24.
The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.
在过去十年中,美国和全球的肥胖人口呈压倒性增长。2008 年,全球超重成年人的数量超过 10 亿。肥胖相关的健康危害非常严重,包括心脏病、睡眠呼吸暂停、糖尿病和癌症。尽管生活方式的改变是控制体重最直接的方法,但很大一部分人可能无法仅依赖这种方法。因此,开发抗肥胖治疗药物代表着一个重大的未满足的医疗需求。从历史上看,抗肥胖药物治疗不安全且效果有限。对食欲和代谢生物学的更好理解为开发可能为体重管理提供更安全、更有效的替代药物提供了机会。本文综述了目前市场上和正在开发中的抗肥胖治疗药物,根据其作用靶点和作用机制进行分类。它应该为未来的抗肥胖药物开发建立一个预期的路线图。